A study of tipifarnib in HRAS-mutant specific models demonstrated that tipifarnib inhibits tumor growth in patient-derived xenograft (PDX) models of head and neck squamous cell carcinoma (HNSCC) [32] and transgenic murine models of thyroid cancer [33]. Here, HRAS is linked to neoplasm.